LMNA Antibody

Code CSB-RA013003A0HU
Size US$350
  • IHC image of CSB-RA013003A0HU diluted at 1:115 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-RA013003A0HU diluted at 1:115 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunofluorescence staining of Hela cells with CSB-RA013003A0HU at 1:38, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L).

  • Immunoprecipitating Lamin A/C in Hela whole cell lysate
    Lane 1: Rabbit control IgG instead of CSB-RA013003A0HU in Hela whole cell lysate. For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000)
    Lane 2: CSB-RA013003A0HU (3μg) + Hela whole cell lysate (500μg)
    Lane 3: Hela whole cell lysate (20μg)

  • Overlay histogram showing Hela cells stained with CSB-RA013003A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then permeabilized with 0.3% Triton X-100 for 2 min. The cells were then incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-rabbit IgG (H+L) at 1/200 dilution for 1 h at 4°C. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P02545
Target Names LMNA
Alternative Names 70 kDa lamin antibody; Cardiomyopathy dilated 1A (autosomal dominant) antibody; CDCD1 antibody; CDDC antibody; CMD1A antibody; CMT2B1 antibody; EMD2 antibody; FPL antibody; FPLD antibody; FPLD2 antibody; HGPS antibody; IDC antibody; Lamin A antibody; Lamin A/C antibody; Lamin A/C like 1 antibody; Lamin antibody; Lamin C antibody; lamin-a antibody; Lamin-A/C antibody; LDP1 antibody; LFP antibody; LGMD1B antibody; Limb girdle muscular dystrophy 1B (autosomal dominant) antibody; LMN 1 antibody; LMN A antibody; LMN C antibody; LMN1 antibody; LMNA antibody; LMNA_HUMAN antibody; LMNC antibody; LMNL1 antibody; Prelamin A/C antibody; PRO1 antibody; Renal carcinoma antigen NY REN 32 antibody; Renal carcinoma antigen NY-REN-32 antibody; Renal carcinoma antigen NYREN32 antibody
Species Reactivity Human
Immunogen A synthesized peptide derived from human LMNA
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Monoclonal
Isotype Rabbit IgG
Purification Method Affinity-chromatography
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form Liquid
Tested Applications ELISA, IHC, IF, FC, IP
Recommended Dilution
Application Recommended Dilution
IHC 1:50-1:200
IF 1:20-1:200
IP 1:200-1:1000
Protocols ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol
Immunoprecipitation (IP) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Plays an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics. Required for normal development of peripheral nervous system and skeletal muscle and for muscle satellite cell proliferation
Gene References into Functions
  1. Lamin A-C interaction with Nestin and its role in the tumor senescence.Nestin stabilizes lamin A-C to protect tumor cells from senescence. PMID: 30190500
  2. Among the 120 dilated cardiomyopathy patients 13 (10.8%) had LMNA variants. A novel recurrent LMNA E115M variant was the most frequent in familial DCM. PMID: 29386531
  3. lamin A/C interacts with Notch signaling, thereby influencing cellular differentiation, and point mutation in LMNA could halt this interaction PMID: 29040816
  4. Mutations in LMNA cause autosomal dominant severe heart disease, accounting for 10% of Dilated Cardiomyopathy . PMID: 29175975
  5. ZMPSTE24-dependent cleavage of prelamin A and the eight known disease-associated ZMPSTE24 missense mutations, were examined. PMID: 29794150
  6. The LMNA-NTRK1 fusion was likely the molecular driver of tumorigenesis and metastasis in this patient, and the observed effectiveness of crizotinib treatment provides clinical validation of this molecular target. PMID: 30134855
  7. Three heterozygous missense mutations were identified in unrelated patients - p. W520R (c.1558T > C), p.T528R (small es, Cyrillic.1583capital ES, Cyrillic > G) and p.R190P (c.569G > C). We consider these variants as pathogenic, leading to isolated DCM with conduction defects or syndromic DCM forms with limb-girdle muscular dystrophy and Emery- Dreifuss muscular dystrophy. PMID: 29770364
  8. The functional integrity of lamin and nesprin-1 is thus required to modulate the FHOD1 activity and the inside-out mechanical coupling that tunes the cell internal stiffness to match that of its soft, physiological-like environment. PMID: 28455503
  9. The role of 1B and 2B domains in modulating elastic properties of lamin A. PMID: 27301336
  10. progerin is upregulated in human dilated cardiomyopathy hearts and strongly correlates with left ventricular remodeling PMID: 29702688
  11. Data indicate that patients with truncation mutations in LMNA (lamin A/C) had an earlier occurrence of cardiac conduction disturbance and low left ventricular ejection fraction, than those with missense mutations. PMID: 29237675
  12. A novel truncating LMNA mutation associated with Cardiac conduction disorders and dilated cardiomyopathy was discovered in this family characterized by gender differences in clinical severity in LMNA carriers PMID: 29628476
  13. We find no evidence for an elevated mutation rate in progerin-expressing cells. We conclude that the cellular defect in HGPS cells does not lie in the repair of DNA damage per se. PMID: 28477268
  14. pathogenic gene mutations in LMNA and MYBPC3 alter RNA splicing and may have a role in heart disease PMID: 28679633
  15. Patients with the heterozygous LMNA p.T10I mutation have distinct clinical features and significantly worse metabolic complications compared with other patients with atypical progeroid syndrome as well as patients with Hutchinson-Gilford progeria syndrome. PMID: 29267953
  16. Results suggest that lamin A/C might constitute a type of epithelial marker that better signifies EMT and MET in prostate cancer tissue, since a decrease in lamin A/C expression in Gleason score (GS) 4 is likely associated with the EMT process, while the re-expression of lamin A/C in GS 5 is likely linked with MET. PMID: 29665450
  17. Using cardiomyocytes derived from human induced pluripotent stem cells carrying different LMNA mutations as model for dilated cardiomyopathy, demonstrate that PTC124 induces translational read-through over the premature stop codon and restores production of the full-length protein. PMID: 28754655
  18. This study represents a comprehensive report on relative frequency of CMD in the UK population, indicating MDC1A as the most common CMD subtype (37.35%). PMID: 28688748
  19. in differentiating myoblasts, nuclear HSPB2 compartments sequester lamin A. PMID: 28854361
  20. A mutation in the gene encoding Lamin A/C (LMNAp.R331Q ) led to reduced maximal force development through secondary disease remodelling in patients suffering from dilated cardiomyopathy. PMID: 28436080
  21. In embryonic cells upregulation of lamin A disturbs lamin C, which may influence gene expression. PMID: 27534416
  22. our data demonstrate the occurrence of lamin A/NF-Y interaction and suggest a possible role of this protein complex in regulation of NF-Y function in cell proliferation. PMID: 27793050
  23. Findings provide evidence that lamin A mutants (called progerin) activates the DNA damage response pathway and that dysregulation of this pathway may be responsible for the development of cardiovascular pathology in patients with Hutchinson-Gilford progeria syndrome. PMID: 28423660
  24. Type-2 familial partial lipodystrophy (FPLD2) is a rare autosomal dominant lipodystrophic disorder due to mutations in LMNA. PMID: 28408391
  25. The metabolic features of women with the Dunnigan variety of familial partial lipodystrophy, caused by several missense mutations of LMNA, are reported. PMID: 28443701
  26. UVA-induced progerinlamin A complex formation was largely responsible for suppressing 53BP1-mediated NHEJ DSB repair activity. The present study is the first to demonstrate that UVA-induced progerin upregulation adversely affects 53BP1-mediated NHEJ DSB repair in human keratinocytes via progerinlamin A complex formation. PMID: 28498430
  27. Suggest NF-YAs and lamin A expression levels as novel potential biomarkers useful to identify G1 endometrial carcinoma patients with risk of recurrence. PMID: 27974701
  28. Finally, we demonstrate Lamins as the major factors in reliable miR-218 and miR-129 functions for breast cancer progression. Our findings uncover a new miRNA-mediated regulatory network for different Lamins and provide a potential therapeutic target for breast cancer. PMID: 29378184
  29. Data indicates that D243Gfs*4 LMNA as a mutation causing a severe form of cardiomyopathy with conduction defects, and suggest CX43 downregulation as a possible molecular mechanism leading to the conduction defects observed in mutation carriers. PMID: 29197877
  30. two novel RNA isoforms of LMNA produced through alternative splicing PMID: 28857661
  31. Lamin A/C is an autoantigen in Han Chinese patients with confirmed Sjogren's syndrome. Lamin A/C shares similar epitopes with U1RNP. PMID: 27835913
  32. it was demonstrated that suspension state promoted the reattachment of breast tumor cells by up-regulating lamin A/C via cytoskeleton disruption. These findings highlight the important role of suspension state for tumor cells in tumor metastasis. PMID: 28919351
  33. In this report we show that increased self-association propensity of mutant LA modulates the LA-LB1 interaction and precludes the formation of an otherwise uniform laminar network. Our results might highlight the role of homotypic and heterotypic interactions of LA in the pathogenesis of DCM and hence laminopathies in the broader sense. PMID: 28844980
  34. Familial partial lipodystrophy type 2 (FPLD2) is caused by an autosomal dominant mutation in the LMNA gene. FPLD2-adipocytes appear to accumulate markers of autophagy and catabolize triglycerides at higher levels than control adipocytes. PMID: 29108996
  35. we demonstrate that BAF is necessary to modulate prelamin A effects on chromatin structure PMID: 26701887
  36. Dysmorphic nuclei in patients with an LMNA mutation correlate with the age of heart disease presentation. PMID: 29149195
  37. These results suggest that the nuclear lamins and progerin have marginal roles in the activation of the antioxidant Nrf2 response to arsenic and cadmium. PMID: 28229933
  38. developed a proteomic analysis of plasma samples from a family showing history of dilated cardiomyopathy caused by a LMNA mutation, which may lead to premature death or cardiac transplant PMID: 27457270
  39. Exome sequencing of the proband revealed an extremely rare missense heterozygous variant c.1711_1712CG>TC; p.(Arg571Ser) in LMNA which was confirmed by Sanger sequencing in both the patients. Interestingly, the mutation had no effect on mRNA splicing or relative expression of lamin A or C mRNA and protein in the lymphoblasts PMID: 28686329
  40. Case Report: pathogenic LMNA mutation gives unifying diagnosis explaining arrhythmogenic right ventricular cardiomyopathy and Charcot-Marie-Tooth type 2B1 phenotypes. PMID: 27405450
  41. Standard Sanger sequencing of LMNA exon 11 DNA from blood-derived WBCs and cultured skin fibroblasts sequenced at passages 1, 3 and 8 detected differing progerin-producing mutations in the same nucleotide of the exon 11 intronic splice donor site (see online supplementary figure. PMID: 27920058
  42. the CNOT1-LMNA-Hedgehog signaling pathway axis exerts an oncogenic role in osteosarcoma progression, which could be a potential target for gene therapy. PMID: 28188704
  43. Pathogenic variants in the LMNA gene responsible for nearly 10%-15%% of Familial Dilated Cardiomyopathy cases. PMID: 27736720
  44. low lamin A but not lamin C expression in pleural metastatic cells could represent a major actor in the development of metastasis, associated with epithelial to mesenchymal transition and could account for a pejorative factor correlated with a poor Performance status. PMID: 28806747
  45. These results propose a mechanism for progerin-induced genome instability and accelerated replicative senescence in Hutchinson-Gilford progeria syndrome. PMID: 28515154
  46. LmnA binds AIMP3 via its extreme C-terminus. Together these findings provide a structural insight for understanding the interaction between AIMP3 and LmnA in AIMP3 degradation. PMID: 28797100
  47. The R482W mutation results in a loss of function of differentiation-dependent lamin A binding to the MIR335 locus and epigenetic regulation of adipogenesis. PMID: 28751304
  48. Pathogenic variants of the LMNA gene were determined in nine families with familial partial lipodystrophy PMID: 28641778
  49. The interaction of progerin with lamin A/C contributes to the development of the senescence phenotype of Hutchinson-Gilford progeria syndrome and aged cells. PMID: 27617860
  50. we expressed a LEMD2 transgene alone or in combination with lamin C in these cells and observed no restoration of peripheral heterochromatin in either case. We conclude that in contrary to the B-tether, the A-tether has a more intricate composition and consists of multiple components that presumably vary, at differing degrees of redundancy, between cell types and differentiation stages PMID: 28056360
  51. These abnormalities are associated with increased transforming growth factor-b signaling and defects in matrix metalloproteinase 9 activity. Our data demonstrate that lamin A/C gene mutations responsible for FPLD2 and related lipodystrophies are associated with transforming growth factor-beta activation PMID: 27845687
  52. Case Report: identical twin brothers with same lamin A/C missense mutation where one developed dilated cardiomyopathy/heart failure and the other remained asymptomatic. PMID: 26951916
  53. p.S143P lamin A/C affects normal lamina structure and influences the cellular stress response, homeostasis and viability. PMID: 27235420
  54. This case demonstrates that accumulation of prelamin A, independent of the loss of function of ZMPSTE24 metallopeptidase that catalyzes processing of prelamin A, can cause a progeroid disorder and that a cell biology assay could be used in precision medicine to identify a potential therapy. PMID: 27034136
  55. A novel homozygous LMNA missense variant identified in a patient presenting poikiloderma, joint stiffness and distal acroosteolysis without features of muscle weakness. PMID: 26733286
  56. c.1824C>T remains the most frequent mutation in Hutchinson-Gilford Progeria Syndrome patients, other mutations in the LMNA gene have been reported that result in increased usage of the cryptic splice site. PMID: 27374873
  57. We present a female patient with a unique phenotype including rare atypical progeroid syndrome and dilated cardiomyopathy. Genetic mutation detection in the gene LMNA revealed a novel heterozygous de novo mutation p.Leu59Val located in the first exon of gene LMNA c.175C>CG. PMID: 27265359
  58. We identified a novel LMNA splice-site mutation by exome sequencing in a family with DCM and arrhythmia. The fibroblast studies that were conducted showed monoallelic expression of the normal allele which is consistent with a haploinsufficient mechanism. PMID: 27182706
  59. LMNA-related heart disease was associated with a high incidence of phenotypic progression and adverse arrhythmic and nonarrhythmic events over long-term follow-up. The index cardiac phenotype did not predict adverse events. PMID: 27884249
  60. R321X is the first LMNA mutant identified to date, which mislocalizes into the endoplasmic reticulum. PMID: 27421120
  61. A-type lamin-dependent Caveolin-2 homo-oligomerization in the inner nuclear membrane microdomain is a precondition for pY19-Caveolin-2-mediated insulin-response epigenetic activation at the nuclear periphery. PMID: 27552914
  62. Disruption of PCNA-lamins A/C interactions by prelamin A induces DNA replication fork stalling PMID: 27676213
  63. the LMNA lipodystrophy mutations that we examined did not lead to prelamin A accumulation PMID: 27841971
  64. Suggest that an increased ventilatory response during exercise might reveal a preclinical manifestation of dilated cardiomyopathy in LMNA mutation carriers. PMID: 27966284
  65. Promoter hypermethylation is a mechanism for lamin A/C silencing in a subset of neuroblastoma cells. PMID: 28422997
  66. Desmin, Lamin A/C, MMP9, and histone H4 were upregulated in the placental villi of women experiencing early pregnancy loss. PMID: 26947931
  67. Novel lamin A/C mutation (V445E) with a sudden death form of familial left ventricular non-compaction. The reduced sodium current in mutant LMNA may account for the advent of malignant ventricular arrhythmias. The altered structures of three beta sheets and side chains may partially explain the aggregation of lamin A/C protein subjacent to the nuclear envelope. PMID: 25829471
  68. we identified a nonsense mutation expected to affect the LTD of LMNA in a 4-generation family with AF. This discovery expands the mutation spectrum of LMNA and indicates the importance of LMNA in AF. PMID: 27373676
  69. we describe two MADA patients with progressive skeletal changes, absent breast development, and cataract in addition to the classical MAD phenotype. Both patients were found to be homozygous for the Ala529Val mutation of the LMNA gene. PMID: 27100822
  70. Variant c.513+45T>G in the LMNA gene is new intronic splicing mutation which is responsible for progressive cardiac conduction defects and variable myopathy. PMID: 27717888
  71. Cardiac involvement as a consequence of LMNA mutations generally has a more aggressive natural history than other forms of non-ischemic dilated cardiomyopathy. A high index of suspicion and prompt referral for genetic testing are essential for appropriate therapeutic management PMID: 25656816
  72. Although it is previously known that alterations in the rod domain of type A lamins are involved in cardiac and neuromuscular diseases, the current observation shows that exon 1 LMNA mutations may be associated with partial lipodystrophy without any cardiac and neurological abnormalities, at least at the time of the presentation. PMID: 26775134
  73. the Lamin C : Lamin A mRNA ratio is increased in breast cancer. PMID: 26732077
  74. Two siblings who presented with generalized lipodystrophy were diagnosed with an atypical progeroid syndrome with a p.D136H mutation in the LMNA gene (NM_005572). We diagnosed a familial atypical progeroid syndrome using whole genome sequencing. PMID: 26122271
  75. A case of laminopathy associated with dilated cardiomyopathy, lipodystrophy and mandibular dysplasia was linked to a mutation in the LMNA gene. PMID: 26922292
  76. discuss a model of progeria where faulty serine 22 phosphorylation compromises phase separation of lamin A polymers, leading to accumulation of functionally impaired lamin A structures PMID: 26922519
  77. specific laminopathy-associated mutations exhibit both positive and negative effects on prelamin A accumulation, indicating that these mutations affect prelamin A processing efficiency in different manners. PMID: 26900797
  78. A novel LMNA mutation was identified in a patient with cardiomyopathy and arrhythmia and a family history of bradyarrhythmia. PMID: 26897078
  79. ZMPSTE24 downregulation is a major contributor in VSMC dysfunctions resulting from LMNA mutations or PI treatments that could translate in early atherosclerosis at the clinical level. PMID: 26724531
  80. Lamin A/C deficiency may serve as an independent risk factor for cervical intra-epithelial neoplasia development and as an indicator for preventive therapy in cervical cancer. PMID: 26537870
  81. This study demonistrated that Muscle MRI/CT identifies a similar pattern of muscle fatty infiltration in patients with mutations in the EMD or the LMNA genes. PMID: 26573435
  82. expression of wild-type LMNA restores the mechanical properties of mutant Neonatal rat ventricular myocytes. PMID: 26309016
  83. the C to T mutation at the rs4641 locus of LMNA could enhance the risk of DCM, and that rs4641 represented a genetic susceptibility locus. PMID: 26634508
  84. Lamin A promotes SIRT6-dependent DNA-PKcs (DNA-PK catalytic subunit) recruitment to chromatin. PMID: 26549451
  85. Data show that all-trans retinoic acid acts synergistically with rapamycin reducing progerin and prelamin A. PMID: 26359359
  86. Development of tumor initiating cells in neuroblastoma is due to an increased expression of MYCN gene. In neuroblastoma an inverse relationship exists between LMNA and MYCN expression. PMID: 26439802
  87. The cardiomyocytes carrying the LMNA D192G mutation have an increased nuclear Young modulus compared to control NRVMs as well as NRVMs expressing wild-type LMNA. PMID: 26323789
  88. Data show that lamins A and B are differently processed in staurosporine and beta-Amyloid peptide fragments Abeta42-treated cells. PMID: 26876308
  89. interactions between SIM3 of lamin A and a putative SUMO2-modified protein plays an important role in the reorganization of the nuclear lamina at the end of mitosis. PMID: 26921507
  90. The study identified three patients with Emery-Dreifuss muscular dystrophy exhibiting the same dominant LMNA mutation and presenting with a spectrum of severe cardiac abnormalities. PMID: 26165385
  91. The findings unveil a unique mechanism where the nuclear periphery proteins lamin-A/C, LAP2alpha and BAF1 are assembled into a protein complex during mitosis in order to regulate assembly and positioning of the mitotic spindle. PMID: 26092935
  92. The authors find that LAP2alpha (lamina-associated polypeptide-alpha) interacts with lamin A, while its interaction with progerin is significantly reduced. PMID: 26312502
  93. our studies demonstrate that lamin A/C plays a significant role in the differentiation of both osteoblasts and adipocytes by regulating some of the elements of Wnt/b-catenin signaling during early MSC differentiation PMID: 25846419
  94. The accumulation of mutant lamin A compromised prophase to prometaphase transition leading to invaginations of the nuclear lamina, nuclear fragmentation and impaired chromosome condensation. PMID: 26029982
  95. Three-dimensional mapping of the lamin A-matrin-3 interface showed that the LMNA truncating mutation Delta303, which lacks the matrin-3 binding domain, was associated with an increased distance between lamin A and matrin-3. PMID: 25948554
  96. Sustained accumulation of prelamin A and depletion of lamin A/C both cause oxidative stress and mitochondrial dysfunction but induce different cell fates. PMID: 25996284
  97. LMNA mutations activate an intracellular signaling pathway and alter the redox homeostasis of muscle tissue. PMID: 25996830
  98. The tail domain of lamin B1 is more strongly modulated by divalent cations than lamin A. PMID: 25807068
  99. We report for the first time the frequent expression of a 270-nt-deleted prelamin A transcript (encoded by LMNA) that had only been evidenced before in patients affected with restrictive dermopathy PMID: 25649378
  100. Phosphorylation of lamins determines their structural properties and signaling functions. PMID: 25793944

Show More

Hide All

Involvement in disease Emery-Dreifuss muscular dystrophy 2, autosomal dominant (EDMD2); Emery-Dreifuss muscular dystrophy 3, autosomal recessive (EDMD3); Cardiomyopathy, dilated 1A (CMD1A); Lipodystrophy, familial partial, 2 (FPLD2); Limb-girdle muscular dystrophy 1B (LGMD1B); Charcot-Marie-Tooth disease 2B1 (CMT2B1); Hutchinson-Gilford progeria syndrome (HGPS); Cardiomyopathy, dilated, with hypergonadotropic hypogonadism (CMDHH); Mandibuloacral dysplasia with type A lipodystrophy (MADA); Lethal tight skin contracture syndrome (LTSCS); Heart-hand syndrome Slovenian type (HHS-Slovenian); Muscular dystrophy congenital LMNA-related (MDCL)
Subcellular Location Nucleus, Nucleus envelope, Nucleus lamina, Nucleus, nucleoplasm
Protein Families Intermediate filament family
Tissue Specificity In the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle cells (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degener
Database Links

HGNC: 6636

OMIM: 115200

KEGG: hsa:4000

STRING: 9606.ENSP00000357283

UniGene: Hs.594444

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1